10:28 AM EDT, 03/25/2024 (MT Newswires) -- BeyondSpring ( BYSI ) said Monday that the first patient has been dosed in a phase 2 investigator-initiated trial of pembrolizumab, plinabulin plus etoposide/platinum for first-line extensive-stage small-cell lung cancer, or ES-SCLC.

The study, conducted in China, will evaluate the efficacy and safety of this drug combination in first-line ES-SCLC. The primary endpoint is the 12-month progression-free survival rate, the company said.

The trial is in collaboration with Merck ( MRK ) , the company added.

Shares of BeyondSpring ( BYSI ) were more than 1% lower in recent trading.

Price: 3.05, Change: -0.07, Percent Change: -2.24